Search results for "LSA"

showing 10 items of 832 documents

RUPTURE OF A LEFT SINUS OF VALSALVA ANEURYSM INTO THE PULMONARY ARTERY.

2006

Sinus of Valsalva aneurysm is a rare congenital defect and the diagnosis is usually made after it ruptures. Very few cases of non-complicated sinus of Valsalva aneurysm have been published. The anomaly most often involves the right coronary sinus and less frequently the non-coronary sinus. A case with left sinus of Valsalva has not been reported. Since the aortic valve occupies a central position in the base of the heart, rupture of a sinus of Valsalva aneurysm can occur in any of the four heart chambers. Rupture into the pulmonary artery is very rare and is mostly associated with other congenital cardiopathies. ª 2005 The European Society of Cardiology. Published by Elsevier Ltd. All right…

AdultMaleAortic valvemedicine.medical_specialtyHeart.chambersAneurysm RupturedPulmonary ArteryMyocardial ruptureDiagnosis DifferentialAneurysmInternal medicinemedicine.arteryHIV Seropositivityotorhinolaryngologic diseasesHumansMedicineRadiology Nuclear Medicine and imagingcardiovascular diseasesHeart AneurysmSinus (anatomy)Coronary sinusbusiness.industryGeneral MedicineSinus of Valsalvamedicine.diseaseAneurysmEchocardiography Doppler Colorbody regionsmedicine.anatomical_structurePulmonary arterycardiovascular systemCardiologyCardiology and Cardiovascular Medicinebusinesscirculatory and respiratory physiologyRupture into the pulmonary artery
researchProduct

Latency of interictal epileptiform discharges in long-term EEG recordings in epilepsy patients.

2015

AbstractPurposeTo assess the latency of interictal epileptiform discharges (IED) and seizures in long-term EEG recordings of patients with epilepsy.MethodIED latency was measured in 210 consecutive patients (mean (SD) age 38.6±13.9 years) with active epilepsy and the relationship to clinical variables was analyzed retrospectively. Median duration of EEG recording was 101.5h (95% confidence interval [CI] 92 to 117h).ResultsIEDs were absent in 45 (21.4%) and present in 165 (78.6%) patients who had a longer duration (p<0.001) and early onset (p<0.01) of epilepsy and more often had IEDs in prior standard EEGs (p<0.01), a structural etiology (OR 2.4, CI: 2.1–2.7), or temporal lobe epilepsy (OR 9…

AdultMaleClinical variablesTime FactorsClinical NeurologyVideo RecordingElectroencephalographyEeg recordingEpilepsySeizuresMedicineHumansIctalLatency (engineering)Negative studiesRetrospective StudiesLong-term EEGEpilepsymedicine.diagnostic_testbusiness.industryBrainElectroencephalographyGeneral MedicineInterictal epileptiform dischargesmedicine.diseaseConfidence intervalNeurologyAnesthesiaLatencyAnticonvulsantsFemaleNeurology (clinical)businessSeizure
researchProduct

Correction to: Adjunctive Brivaracetam in Focal Epilepsy: Real‑World Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST)

2021

In randomized controlled trials, add-on brivaracetam (BRV) reduced seizure frequency in patients with drug-resistant focal epilepsy. Studies performed in a naturalistic setting are a useful complement to characterize the drug profile.This multicentre study assessed the effectiveness and tolerability of adjunctive BRV in a large population of patients with focal epilepsy in the context of real-world clinical practice.The BRIVAFIRST (BRIVAracetam add-on First Italian netwoRk STudy) was a retrospective, multicentre study including adult patients prescribed adjunctive BRV. Patients with focal epilepsy and 12-month follow-up were considered. Main outcomes included the rates of seizure-freedom, s…

AdultMaleDrug Resistant EpilepsyLevetiracetamEpilepsy CNS therapyCorrectionMiddle AgedSettore MED/26PyrrolidinonesPsychiatry and Mental healthTreatment OutcomeItalyChemotherapy AdjuvantHumansPharmacology (medical)AnticonvulsantsFemaleNeurology (clinical)Epilepsies PartialRetrospective Studies
researchProduct

Effectiveness of eslicarbazepine acetate in dependency of baseline anticonvulsant therapy: Results from a German prospective multicenter clinical pra…

2019

Abstract Eslicarbazepine acetate (ESL) is a third-generation antiepileptic drug (AED) approved as monotherapy for partial-onset seizures in adults and as adjunctive therapy in patients aged above 6 years in the European Union (EU). The prospective observational Zebinix Effects in DEpendency of BAseline Conditions (ZEDEBAC) study aimed at investigating the effectiveness of ESL in clinical practice, with ESL being administered as monotherapy (mono group), as only add-on to a current monotherapy (1 + group), or as add-on to ≥ 2 baseline AEDs (≥ 2 + group). In total, 237 patients were included, 35 in the mono group, 114 in the 1 +, and 88 in the ≥ 2 + group. Six-month retention rates were 93.9%…

AdultMaleDrug Resistant Epilepsymedicine.medical_specialtyYoung Adult03 medical and health sciencesBehavioral NeuroscienceEpilepsy0302 clinical medicineSodium channel blockerRefractoryDibenzazepinesSeizuresInternal medicineHumansMedicinemedia_common.cataloged_instanceProspective Studies030212 general & internal medicineEuropean unionAgedmedia_commonbusiness.industryMiddle Agedmedicine.diseaseNeurologyEslicarbazepine acetateConcomitantAnticonvulsantsFemaleObservational studyNeurology (clinical)businessHyponatremia030217 neurology & neurosurgerySodium Channel Blockersmedicine.drugEpilepsy &amp; Behavior
researchProduct

Treatment of Ulcerative Colitis with Olsalazine and Sulphasalazine: Efficacy and Side-Effects

1988

The effects of olsalazine were studied mainly in patients with ulcerative colitis who were intolerant to sulphasalazine, and for relapse prevention. A crossover design with sulphasalazine, 3 g/day, and olsalazine, 1.5 g/day, was applied to compare the side-effects of each drug and to evaluate their therapeutic efficacy. A total of 41 patients with mild or moderately severe left-sided colitis or proctitis were assigned to a randomized treatment schedule. Olsalazine and sulphasalazine were similar in their therapeutic efficacy. Twelve patients complained of adverse effects while on sulphasalazine and 4 patients during olsalazine treatment (p less than 0.05). It is concluded that olsalazine is…

AdultMaleDrugmedicine.medical_specialtymedia_common.quotation_subjectRelapse preventionGastroenterologyRandom AllocationDouble-Blind MethodInternal medicinemedicineHumansProctitisColitisAdverse effectProctitismedia_commonOlsalazineClinical Trials as Topicbusiness.industryGastroenterologymedicine.diseaseUlcerative colitisCrossover studySulfasalazineAminosalicylic AcidsColitis UlcerativeFemalebusinessmedicine.drugScandinavian Journal of Gastroenterology
researchProduct

Levetiracetam in the prophylaxis of migraine with aura: a 6-month open-label study.

2006

OBJECTIVE: To evaluate the efficacy of levetiracetam as prophylactic treatment for migraine with aura with high frequency of attacks. BACKGROUND: Migraine with aura with high frequency of attacks could represent a very demanding therapeutic problem. Efficacy of the antiepileptic drug, lamotrigine, has been reported in this form of migraine. Levetiracetam is a new antiepileptic drug with an excellent tolerability profile. Mechanisms of action of this drug remain largely unknown, but recently, it has been shown to exert inhibitory effects on neuronal-type calcium channels. METHODS: We performed a small open-label trial treating 16 patients affected by migraine with aura with high frequency of…

AdultMaleLevetiracetamAuraMigraine with AuraLamotrigineMedicineHumansPharmacology (medical)Prospective StudiesProspective cohort studyPharmacologybusiness.industryMiddle Agedmedicine.diseasePiracetamMigraine with auraTolerabilityMigraineAnesthesiaAnticonvulsantsFemaleNeurology (clinical)Levetiracetammedicine.symptombusinessSomnolencemedicine.drugClinical neuropharmacology
researchProduct

Accuracy of the fetal cerebroplacental ratio for the detection of intrapartum compromise in nonsmall fetuses

2018

Objective: To study the accuracy of the cerebroplacental ratio (CPR) for the detection of intrapartum fetal compromise (IFC) in fetuses growing over the 10th centile.Methods: This was a prospective...

AdultMaleMiddle Cerebral Arterymedicine.medical_specialtyeducationGestational AgeFetal DistressUltrasonography PrenatalUmbilical Arteries03 medical and health sciences0302 clinical medicinePredictive Value of TestsPregnancymedicineFetal growthBirth WeightHumansProspective Studies030212 general & internal medicinereproductive and urinary physiologyFetus030219 obstetrics & reproductive medicineObstetricsbusiness.industryInfant NewbornPregnancy OutcomeReproducibility of ResultsObstetrics and GynecologyFetal dopplerPulsatile Flowembryonic structuresPediatrics Perinatology and Child HealthFemalebusinessThe Journal of Maternal-Fetal &amp; Neonatal Medicine
researchProduct

Subregional Pathology of the Amygdala Complex and Entorhinal Region in Surgical Specimens From Patients With Pharmacoresistant Temporal Lobe Epilepsy

2000

The hippocampus, amygdala complex, and entorhinal region represent anatomically linked limbic structures of the mesiotemporal lobe. Chronic seizures and mnestic deficits in patients with pharmacoresistant mesial temporal lobe epilepsy (TLE) appear to correlate with distinct patterns of histopathological alterations in these areas. The complex anatomical organization of the amygdala and entorhinal region, however, render a detailed neuropathological evaluation of surgical specimens difficult. In this study, we present a combined cytoarchitectonical, pigmentarchitectonical, myelinarchitectonical, and immunohistochemical reconstruction of the amygdala, entorhinal region, and hippocampus from s…

AdultMalePathologymedicine.medical_specialtyAdolescentDrug ResistanceHippocampusAutopsyAmygdalaPathology and Forensic MedicineTemporal lobeCentral nervous system diseaseCellular and Molecular NeuroscienceEpilepsyBasal (phylogenetics)medicineEntorhinal CortexHumansGliosisSclerosisGeneral MedicineMiddle AgedAmygdalamedicine.diseaseTemporal LobeLobemedicine.anatomical_structureEpilepsy Temporal Lobenervous systemNeurologyChild PreschoolAnticonvulsantsFemaleNeurology (clinical)Psychologypsychological phenomena and processesJournal of Neuropathology &amp; Experimental Neurology
researchProduct

Zonisamide in children and young adults with refractory epilepsy: an open label, multicenter Italian study

2009

Summary Purpose To report on the first multicenter Italian experience with zonisamide as an add-on drug for refractory generalised or partial epilepsy in children, adolescents and young adults. Methods The patients were enrolled in a prospective, add-on, open-label treatment study from eight Italian centres for children and adolescent epilepsy care. Eighty-two young patients (45 males, 37 females), aged between 3 and 34 years (mean 13.1 years), all affected by partial (47) or generalised (35) refractory epilepsy, were enrolled in the study. ZNS was added to the baseline therapy at a starting dose of 1 mg/kg/day twice daily. This dose was increased by 2 mg/kg every 1–2 weeks over a period of…

AdultMalePediatricsmedicine.medical_specialtyAdolescentmedicine.medical_treatmentAntiepileptic drugsZonisamideIrritabilityStatistics NonparametricEpilepsyYoung AdultRefractorymedicineHumansNonparametricYoung adultAdverse effectPreschoolChildNeurologic ExaminationEpilepsybusiness.industryStatisticsElectroencephalographyDrug ToleranceIsoxazolesmedicine.diseaseMagnetic Resonance ImagingSettore MED/39 - Neuropsichiatria InfantileEpilepsy; Zonisamide; Pediatric epilepsy; Antiepileptic drugsAnticonvulsantTolerabilityNeurologyItalyZonisamideChild PreschoolAnticonvulsantsFemaleNeurology (clinical)medicine.symptombusinessPediatric epilepsyAntiepileptic drugs; Epilepsy; Pediatric epilepsy; Zonisamide; Adolescent; Adult; Anticonvulsants; Child; Child Preschool; Drug Tolerance; Electroencephalography; Epilepsy; Female; Follow-Up Studies; Humans; Isoxazoles; Italy; Magnetic Resonance Imaging; Male; Neurologic Examination; Statistics Nonparametric; Young Adult; Neurology; Neurology (clinical)medicine.drugFollow-Up Studies
researchProduct

Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy

2004

Purpose: To evaluate the efficacy and safety of levetiracetam (LEV) in refractory crypto/symptomatic, partial or generalised epilepsy in children, adolescents and young adults. Methods: We performed a prospective open label add-on study in 99 patients (age 12 months to 32 years, mean 14 years) with partial or generalised, crypto/symtpomatic seizures. Levetiracetam was added to no more than two baseline AEDs and the efficacy was rated according to seizure type and frequency. Results: LEV was initiated at the starting dose of 10 mg/kg/day with 5-day increments up to 50 mg/kg/day, unless it was not tolerated. Concomitant therapy was generally not modified throughout the study. After a mean fol…

AdultMalePediatricsmedicine.medical_specialtyAdolescentmedicine.medical_treatmentlevetiracetamefficacyIrritabilityStatistics NonparametricEpilepsyDOUBLE-BLINDantiepileptic drugmedicineHumansprospective trialProspective StudiesChildAdverse effectChi-Square DistributionEpilepsybusiness.industryInfantmedicine.diseasePiracetamAnticonvulsantNeurologyTolerabilityEpilepsy in childrenChild PreschoolAnesthesiaEpilepsy syndromesFemaleTRIALNeurology (clinical)Levetiracetammedicine.symptomtolerability PARTIAL SEIZURESbusinessFollow-Up Studiesmedicine.drug
researchProduct